.Attributes Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a typical consequence of 11 months, patients along with metastatic stomach cysts that received biomarker-matched therapies based upon distributing tumor DNA profiling revealed a greater medical advantage than those acquiring incomparable therapy.